The Significance of Remnant Cholesterol and Carotid Intima Media Thickness in Patients With MAFLD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-31

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. To detect the significance of remenant cholesterol in detection severity of MAFLD
2. To detect the significance of carotid intima-media thickness in MAFLD

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Validity of Laboratory Biomarkers in Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) and It's Consequences

NCT06908122

Non-alcoholic Fatty Liver Disease

NOT_YET_RECRUITING

Fatty Liver Disease Collaborative Research in China

NCT02391168

Fatty Liver Fatty Liver, Alcoholic Non-alcoholic Fatty Liver Disease

UNKNOWN

The Relationship Between Morbid Obesity and Carotid Artery Stenosis

NCT03306771

Carotid Artery Diseases Morbid Obesity Metabolic Syndrome

UNKNOWN

Obesity Phenotypes and Its Relation to Cardiovascular Diseases

NCT06092021

Obesity Cardiovascular Diseases

UNKNOWN

Visceral Abdominal Fat, Non Alcoholic Fatty Liver Diseases and Asymptomatic Coronary Atherosclerosis

NCT01282892

Visceral Fat Fatty Liver Atherosclerosis +1 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-alcoholic fatty liver disease (NAFLD) is fatty infiltration of the liver in the absence of other causes of steatosis, such as alcohol consumption characterized by excessive fat accumulation in liver \>5-10% of its weight encompassing a spectrum of increasingly severe clinico-pathological conditions - nonalcoholic fatty liver (NAFL) and nonalcoholic steato-hepatitis (NASH) with or without fibrosis/cirrhosis. Since NAFLD is frequently associated with further metabolic comorbidities such as obesity, type 2 diabetes mellitus, or dyslipidemia, it is generally considered as the hepatic manifestation of the metabolic syndrome A growing body of evidence also indicates that NAFLD is strongly associated with an increased risk of major CVD events and other cardiac complications (ie, cardiomyopathy, cardiac valvular calcification and cardiac arrhythmias), independently of traditional cardiovascular risk factors NAFLD has also been associated with an increase in the carotid intima- media thickness (CIMT), independent of conventional CVD risk factors. CIMT is a marker of early atherosclerosis and has been shown to predict increased risks of myocardial in-farction and stroke Fatty liver index (FLI) has been proposed as an accurate, convenient, and economic surrogate of the severity of NAFLD. Remnant cholesterol refers to the cholesterol content carried by triglyceride-rich lipoproteins, which include non-LDL-C and nonhigh density lipoprotein-cholesterol (HDL-C) A large number of studies have reported that serum remnant cholesterol levels were positively associated with the risk of coronary artery disease NAFLD

, type 2 diabetes , and metabolic syndrome

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Detect the Significance of Remnant Cholesterol in Detection Severity of MAFLD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lipid profile

carotid intima media thickness

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

color doppler

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The study will include adult patients (≥18 years) presented to fibroscan clinic and diagnosed as MAFLD.

Exclusion Criteria

1. Patients Known previous cardiac disease ( cardiovascular disease, heart failure, arrhythmia )
2. Patients Known liver cirrhosis
3. septic patients
4. Patients have malignancy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No